KR20250073542A - 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 - Google Patents
치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 Download PDFInfo
- Publication number
- KR20250073542A KR20250073542A KR1020257015844A KR20257015844A KR20250073542A KR 20250073542 A KR20250073542 A KR 20250073542A KR 1020257015844 A KR1020257015844 A KR 1020257015844A KR 20257015844 A KR20257015844 A KR 20257015844A KR 20250073542 A KR20250073542 A KR 20250073542A
- Authority
- KR
- South Korea
- Prior art keywords
- unsubstituted
- substituted
- compound
- dihydro
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641149P | 2018-03-09 | 2018-03-09 | |
| US62/641,149 | 2018-03-09 | ||
| US201862755163P | 2018-11-02 | 2018-11-02 | |
| US62/755,163 | 2018-11-02 | ||
| PCT/US2019/019557 WO2019173082A1 (en) | 2018-03-09 | 2019-02-26 | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| KR1020207028226A KR102810102B1 (ko) | 2018-03-09 | 2019-02-26 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207028226A Division KR102810102B1 (ko) | 2018-03-09 | 2019-02-26 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250073542A true KR20250073542A (ko) | 2025-05-27 |
Family
ID=67845731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257015844A Pending KR20250073542A (ko) | 2018-03-09 | 2019-02-26 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
| KR1020207028226A Active KR102810102B1 (ko) | 2018-03-09 | 2019-02-26 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207028226A Active KR102810102B1 (ko) | 2018-03-09 | 2019-02-26 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11261192B2 (https=) |
| EP (2) | EP4566612A3 (https=) |
| JP (4) | JP7300460B2 (https=) |
| KR (2) | KR20250073542A (https=) |
| CN (3) | CN117285532A (https=) |
| AU (2) | AU2019231551B2 (https=) |
| BR (1) | BR112020018286A2 (https=) |
| CA (1) | CA3089746A1 (https=) |
| DK (1) | DK3762385T3 (https=) |
| ES (1) | ES3024692T3 (https=) |
| FI (1) | FI3762385T3 (https=) |
| HR (1) | HRP20250517T1 (https=) |
| HU (1) | HUE071131T2 (https=) |
| IL (2) | IL276802B2 (https=) |
| LT (1) | LT3762385T (https=) |
| MX (2) | MX2020009372A (https=) |
| PL (1) | PL3762385T3 (https=) |
| PT (1) | PT3762385T (https=) |
| RS (1) | RS66798B1 (https=) |
| SG (1) | SG11202006906XA (https=) |
| SI (1) | SI3762385T1 (https=) |
| TW (2) | TWI822733B (https=) |
| WO (1) | WO2019173082A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111163780A (zh) | 2017-07-18 | 2020-05-15 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| WO2020150676A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| US20220220115A1 (en) * | 2019-04-09 | 2022-07-14 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| US20220169646A1 (en) * | 2019-04-09 | 2022-06-02 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| BR112021026618A2 (pt) | 2019-06-28 | 2022-06-07 | Shanghai Pharmaceuticals Holding Co Ltd | Composto de pirazolpirimidina, método de preparação do mesmo e aplicações do mesmo |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| AU2020384291A1 (en) * | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| JP2023507797A (ja) * | 2019-12-20 | 2023-02-27 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| AU2020407070A1 (en) * | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| KR20220119658A (ko) * | 2019-12-20 | 2022-08-30 | 리커리엄 아이피 홀딩스, 엘엘씨 | 조합물 |
| AU2020404996A1 (en) * | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| CN113387962A (zh) * | 2020-03-12 | 2021-09-14 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| MX2022014131A (es) * | 2020-05-15 | 2023-01-05 | Recurium Ip Holdings Llc | Monoterapias y terapias de combinacion. |
| MX2022015646A (es) * | 2020-06-11 | 2023-02-27 | Recurium Ip Holdings Llc | Métodos para elaborar compuestos inhibidores de wee1. |
| CA3180664A1 (en) | 2020-06-17 | 2021-12-23 | Yuli Xie | Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor |
| WO2022011391A1 (en) * | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2022076638A1 (en) * | 2020-10-08 | 2022-04-14 | Academia Sinica | Catalysts and their uses in one-pot diastereoselective synthesis of remdesivir |
| CN116848118A (zh) * | 2021-02-09 | 2023-10-03 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物 |
| WO2022171126A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物 |
| WO2022171088A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物 |
| AU2022259496A1 (en) * | 2021-04-12 | 2023-10-12 | Recurium Ip Holdings, Llc | Wee1 compound for treating uterine serous carcinoma |
| KR20240004539A (ko) | 2021-04-30 | 2024-01-11 | 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 | Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도 |
| WO2022251224A1 (en) * | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
| CN118019978A (zh) * | 2021-06-23 | 2024-05-10 | 里科瑞尔姆Ip控股有限责任公司 | Wee1抑制剂和用于治疗癌症的方法 |
| WO2023280180A1 (zh) * | 2021-07-05 | 2023-01-12 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物 |
| CN117751122A (zh) * | 2021-08-11 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| CN117751123A (zh) * | 2021-08-31 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的5-氟-7H-吡咯并[2,3-d]嘧啶类化合物 |
| CN113735863A (zh) * | 2021-09-29 | 2021-12-03 | 武汉九州钰民医药科技有限公司 | Wee1抑制剂adavosertib的制备工艺 |
| WO2023072301A1 (zh) * | 2021-11-01 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途 |
| EP4431511A4 (en) * | 2021-11-09 | 2025-10-15 | Hangzhou Glubio Pharmaceutical Co Ltd | WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE |
| MX2024007260A (es) * | 2021-12-15 | 2024-06-26 | Recurium Ip Holdings Llc | Uso de terapia de combinacion para tratar el cancer. |
| EP4447974A4 (en) * | 2021-12-15 | 2025-11-26 | Recurium Ip Holdings Llc | WEE1 CANCER INHIBITOR |
| WO2023193789A1 (en) * | 2022-04-08 | 2023-10-12 | Beijing Neox Biotech Limited | Wee1 degrading compounds |
| EP4565238A1 (en) * | 2022-08-05 | 2025-06-11 | Recurium IP Holdings, LLC | Wee1 compound for treating uterine serous carcinoma |
| TW202421151A (zh) * | 2022-09-16 | 2024-06-01 | 美商瑞卡瑞恩Ｉｐ控股有限責任公司 | Ｗｅｅ１抑制劑及用於治療癌症之方法 |
| WO2025076311A1 (en) * | 2023-10-06 | 2025-04-10 | Zeno Management, Inc. | Solid forms of a wee1 inhibitor |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
| WO2026083289A1 (en) | 2024-10-15 | 2026-04-23 | Assia Chemical Industries Ltd. | Solid state forms of azenosertib |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002997A (es) | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| EP1740579B1 (en) | 2004-03-24 | 2015-08-19 | AbbVie Inc. | Tricyclic pyrazole kinase inhibitors |
| US7507748B2 (en) * | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| MX2007007272A (es) | 2004-12-17 | 2007-07-11 | Astrazeneca Ab | 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk. |
| WO2007035963A2 (en) | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| US20100003191A1 (en) | 2006-12-05 | 2010-01-07 | Nagasaki University | Aurone derivative-containing composition for diagnosis |
| CA2671354A1 (en) | 2006-12-08 | 2008-06-12 | Takeda Pharmaceutical Company Limited | Tricyclic compound and medical use thereof |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| US20090156826A1 (en) | 2007-12-12 | 2009-06-18 | Wyeth | Methods for the preparation of hydroxy-substituted aryl sulfamide compounds |
| EP2141163A1 (de) | 2008-07-02 | 2010-01-06 | Bayer Schering Pharma AG | Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| AU2009303444A1 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Azine derivatives and methods of use thereof |
| UY32622A (es) | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| DE102011108708A1 (de) | 2010-09-25 | 2012-03-29 | Merck Patent Gmbh | Flüssigkristallanzeigen und flüssigkristalline Medien mit homöotroper Ausrichtung |
| MX2013010513A (es) | 2011-03-16 | 2013-10-07 | Hoffmann La Roche | Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos. |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| PH12014500869A1 (en) | 2011-10-19 | 2014-06-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
| WO2014062454A1 (en) | 2012-10-15 | 2014-04-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
| CA2902858A1 (en) | 2013-02-28 | 2014-09-04 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| TW201522332A (zh) | 2013-03-01 | 2015-06-16 | Amgen Inc | 經取代之７－酮基－吡啶并［２，３－ｄ］嘧啶及其使用方法 |
| US9650573B2 (en) | 2013-05-14 | 2017-05-16 | Merck Patent Gmbh | Liquid crystalline medium and liquid crystal device |
| SG11201607973XA (en) | 2014-03-24 | 2016-11-29 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP3189551B1 (de) | 2014-09-05 | 2021-01-27 | Merck Patent GmbH | Formulierungen und verfahren zur herstellung einer organischen elektrolumineszenzvorrichtung |
| WO2016138631A1 (en) | 2015-03-03 | 2016-09-09 | Eli Lilly And Company | Imidazo benzamide compounds |
| JP6692423B2 (ja) * | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| KR20170127101A (ko) | 2016-05-10 | 2017-11-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| KR102673813B1 (ko) | 2016-11-04 | 2024-06-10 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| KR102739115B1 (ko) | 2016-12-22 | 2024-12-05 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| JP6717457B2 (ja) | 2017-01-23 | 2020-07-01 | シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド | Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体 |
| KR102390377B1 (ko) | 2017-03-02 | 2022-04-25 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| US11248006B2 (en) | 2017-03-23 | 2022-02-15 | Shanghai De Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
| KR102496480B1 (ko) | 2017-04-25 | 2023-02-06 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 조성물 |
| US11101435B2 (en) | 2017-05-19 | 2021-08-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate platinum and palladium complexes based on biscarbazole and analogues |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN109810111B (zh) | 2017-11-20 | 2023-10-27 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| WO2019134539A1 (zh) | 2018-01-05 | 2019-07-11 | 四川科伦博泰生物医药股份有限公司 | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 |
| WO2019165204A1 (en) | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
| US12220415B2 (en) | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| KR102637792B1 (ko) | 2018-03-22 | 2024-02-19 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 전자 장치 |
| CN108794493B (zh) | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 四氢吡咯并[2,1-h]蝶啶-6(5H)-酮衍生物、其药物组合物、制备方法和应用 |
| CN108794484B (zh) | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
| KR102328435B1 (ko) | 2018-09-11 | 2021-11-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109651337A (zh) | 2018-12-30 | 2019-04-19 | 瑞声科技（南京）有限公司 | 发光组合物及包含该发光组合物的发光层和电致发光器件 |
| KR102860612B1 (ko) | 2019-03-25 | 2025-09-15 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| WO2020210320A1 (en) | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| CN112142748B (zh) | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| JP2023507797A (ja) | 2019-12-20 | 2023-02-27 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| AU2020407070A1 (en) | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| AU2020404996A1 (en) | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
-
2019
- 2019-02-26 EP EP25156816.8A patent/EP4566612A3/en active Pending
- 2019-02-26 JP JP2020547089A patent/JP7300460B2/ja active Active
- 2019-02-26 US US16/971,254 patent/US11261192B2/en active Active
- 2019-02-26 KR KR1020257015844A patent/KR20250073542A/ko active Pending
- 2019-02-26 EP EP19764330.7A patent/EP3762385B1/en active Active
- 2019-02-26 CN CN202311224807.9A patent/CN117285532A/zh active Pending
- 2019-02-26 ES ES19764330T patent/ES3024692T3/es active Active
- 2019-02-26 CN CN201980021575.2A patent/CN111902413B/zh active Active
- 2019-02-26 RS RS20250397A patent/RS66798B1/sr unknown
- 2019-02-26 PT PT197643307T patent/PT3762385T/pt unknown
- 2019-02-26 DK DK19764330.7T patent/DK3762385T3/da active
- 2019-02-26 KR KR1020207028226A patent/KR102810102B1/ko active Active
- 2019-02-26 HR HRP20250517TT patent/HRP20250517T1/hr unknown
- 2019-02-26 FI FIEP19764330.7T patent/FI3762385T3/fi active
- 2019-02-26 WO PCT/US2019/019557 patent/WO2019173082A1/en not_active Ceased
- 2019-02-26 PL PL19764330.7T patent/PL3762385T3/pl unknown
- 2019-02-26 IL IL276802A patent/IL276802B2/en unknown
- 2019-02-26 CN CN202311229341.1A patent/CN117720541A/zh active Pending
- 2019-02-26 MX MX2020009372A patent/MX2020009372A/es unknown
- 2019-02-26 SG SG11202006906XA patent/SG11202006906XA/en unknown
- 2019-02-26 HU HUE19764330A patent/HUE071131T2/hu unknown
- 2019-02-26 LT LTEPPCT/US2019/019557T patent/LT3762385T/lt unknown
- 2019-02-26 AU AU2019231551A patent/AU2019231551B2/en active Active
- 2019-02-26 CA CA3089746A patent/CA3089746A1/en active Pending
- 2019-02-26 SI SI201930929T patent/SI3762385T1/sl unknown
- 2019-02-26 IL IL302171A patent/IL302171B1/en unknown
- 2019-02-26 BR BR112020018286-9A patent/BR112020018286A2/pt active Search and Examination
- 2019-03-04 TW TW108107026A patent/TWI822733B/zh active
- 2019-03-04 TW TW112139998A patent/TWI851451B/zh active
-
2020
- 2020-09-08 MX MX2023010806A patent/MX2023010806A/es unknown
-
2021
- 2021-10-08 US US17/497,355 patent/US20220024939A1/en not_active Abandoned
-
2023
- 2023-06-19 JP JP2023100100A patent/JP7614255B2/ja active Active
- 2023-10-17 AU AU2023251425A patent/AU2023251425B2/en active Active
-
2024
- 2024-08-02 US US18/793,337 patent/US20240391924A1/en active Pending
- 2024-12-26 JP JP2024229980A patent/JP7726563B2/ja active Active
-
2025
- 2025-07-31 JP JP2025128531A patent/JP2025160419A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7726563B2 (ja) | 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン | |
| JP7203816B2 (ja) | １，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン類似体 | |
| WO2023081209A1 (en) | Pi3k inhibitors and methods of treating cancer | |
| CA3037064A1 (en) | Spirocyclic compounds | |
| WO2020210320A1 (en) | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| RU2847224C2 (ru) | Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны | |
| RU2812726C2 (ru) | Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны | |
| HK40043303B (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| HK40043303A (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250514 Application number text: 1020207028226 Filing date: 20200929 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250609 Comment text: Request for Examination of Application |